

## BIOGRAPHICAL SKETCH

Provide the following information for the key personnel listed on Pg 2, beginning with the Principal Investigator. Photocopy this page or follow this format for each person.

NAME	POSITION TITLE		
Richard J. Barth, Jr	Associate Professor of Surgery		
EDUCATION (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)			
INSTITUTION AND LOCATION	DEGREE	YEAR CONFERRED	FIELD OF STUDY
Princeton University, Princeton, NJ	A.B.	1981	Biochemistry
Harvard Medical School, Boston, MA	M.D.	1985	Medicine
New England Deaconess Harvard Surgical Service, Boston, MA	Resident	1985-1988	Surgery
Surgery Branch, National Cancer Institute, Bethesda, MD	Fellow	1988-1990	Immunology
New England Deaconess Harvard Surgical Service, Boston, MA	Resident	1990-1992	Surgery

### A. Positions and Honors.

#### Positions and Employment

- 1993-1998 Assistant Professor of Surgery, Dartmouth Medical School (DMS), Hanover, NH  
1995-2003 Director, Gastrointestinal Oncology Program, Norris Cotton Cancer Center (NCCC), Lebanon, NH  
1999-present Associate Professor of Surgery, DMS  
2002-present Chief, Division of Surgical Oncology, Dartmouth-Hitchcock Medical Center, Lebanon, NH  
2002-2004 Chairman, Clinical Cancer Care Committee, NCCC  
2002-present Co-Director, Immunology and Cancer Immunotherapy Research Program, NCCC  
2003-present Chief of General Surgery, Dartmouth-Hitchcock Medical Center

#### Honors and Awards

- 1995 American Cancer Society Career Development Award  
1998 Milham Award for Clinical Excellence, DMS  
1999 Election to Alpha Omega Alpha  
2000 Election to Society of University Surgeons  
2001 Chairman's Award, Department of Surgery, DMS, for excellence in research, teaching, and clinical care  
2002 The Arthur Naitove Distinguished Teaching Award  
2003 Dartmouth-Mosenthal Surgical Fellowship Award

### B. Selected Peer-Reviewed Publications

- Barth RJ Jr, Bock S, Mule JJ, Rosenberg SA (1990). Unique murine tumor-associated antigens identified by tumor infiltrating lymphocytes. *J Immunol* 144: 1531-1537.
- Barth RJ Jr, Mule JJ, Speiss PJ, Rosenberg SA (1991). Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor infiltrating lymphocytes. *J Exp Med* 173: 647-658.
- Barth RJ Jr, Danforth DN, Venzon DJ, Straus KL, d'Angelo T, Merino MJ, Gerber L (1991). Level of axillary involvement by lymph node metastases in breast cancer is not an independent predictor of survival. *Arch Surg* 126: 574-577.
- Barth RJ Jr, Venzon DJ, Baker AR (1991). The prognosis of melanoma patients with metastases to two or more lymph node areas. *Ann Surg* 214: 125-130.
- Barth RJ Jr, Mule JJ, Asher AL, Sanda MG, Rosenberg SA (1991). Unique murine tumor-associated antigens identified by tumor infiltrating lymphocytes: Tumor specific secretion of interferon gamma and tumor necrosis factor. *J Immunol Meth* 140: 269-279.
- Barth RJ Jr, Merino MJ, Solomon D, Yang JC, Baker AR (1992). A prospective study of the value of core needle biopsy and fine needle aspiration in the diagnosis of soft tissue masses. *Surgery* 112: 536-543.
- Barth RJ Jr, Coppola M, Green WR (1996). The *in vivo* effects of locally secreted IL-10 on the murine anti-tumor immune response. *Ann of Surg Oncol* 3 (4): 381-386.
- Camp BJ, Dyhrman ST, Memoli VA, Mott LA, Barth RJ Jr (1996). *In situ* cytokine production by breast cancer tumor infiltrating lymphocytes. *Ann of Surg Oncol* 3 (2): 176-184.
- Barth RJ Jr, Camp BJ, Martuscello TA, Dain BJ, Memoli VA (1996). The cytokine microenvironment of human colon cancer: Lymphocyte production of TNF and IL-4 predicts improved survival. *Cancer* 78 (6): 1168-1178.
- Mackey MF, Gunn JR, Ting PP, Kikutani H, Dranoff G, Noelle RJ, Barth RJ Jr (1997). Protective immunity induced by tumor vaccines requires interaction between CD40 and its ligand, CD154. *Cancer Res* 57 (13): 2569-2574.

Mackey MF, Gunn JR, Maliszewsky C, Kikutani H, Noelle RJ and Barth RJ Jr (1998). Dendritic cells require maturation via CD40 to generate protective antitumor immunity. *J Immunol* 161: 2094-2098.

Barth RJ Jr (1999). Histologic features predict local recurrence after breast conserving therapy of Phyllodes tumors. *Breast Cancer Res Treat* 57 (3): 291-295.

Lambert LA, Colacchio TA, Barth RJ Jr (2000). Interval hepatic resection of colorectal metastases improves patient selection. *Arch Surgery* 135 (4): 473-480.

Barth RJ J, Mule JJ. "IL-2: Preclinical trials." In: *Biologic Therapy of Cancer: Principle and Practice*, edited by SA Rosenberg, Philadelphia, PA: Williams and Wilkins, 2000.

Gibson GR, Lesnikoski BA, Yoo J, Mott LA, Cady B, Barth RJ Jr (2001) A comparison of ink-directed and traditional whole-cavity re-excision for breast lumpectomy specimens with positive margins. *Ann Surg Oncol* 8 (9): 693-704.

Schwaab T, Weiss JE, Schned AR, Barth RJ Jr (2001). Dendritic cell infiltration in colon cancer. *J Immunother* 24 (2): 130-137.

Lambert LA, Gibson GR, Maloney M, Durell B, Noelle RJ, Barth RJ Jr (2001). Intranodal immunization with tumor lysate pulsed dendritic cells enhances protective anti-tumor immunity. *Cancer Res* 61: 641-646.

Pipas JM, Mitchell SE, Barth RJ Jr, Vera-Gimon R, Rathmann J, Meyer LP, Wagman RS, Lewis LD, McDonnell C, Colacchio TA, Perez RP (2001). A phase I study of twice weekly gemcitabine and concomitant external beam radiotherapy in patients with adenocarcinoma of the pancreas. *Int J Rad Onc Biol Physics* 50 (5): 1317-1322.

Lambert LA, Gibson GR, Maloney M, Barth RJ Jr (2001). Equipotent generation of protective anti-tumor immunity by various methods of dendritic cell loading with whole cell tumor antigens. *J Immunother* 24 (3): 232-236.

Guyre CA, Fisher JL, Waugh MC, Wallace PK, Tretter CG, Ernstoff MS, Barth RJ Jr (2002). Advantages of hydrophobic culture bags over flasks for the generation of monocyte-derived dendritic cells for clinical applications. *J Immunol Methods* 262 (1-2): 85-94.

Frleta D, Lin JT, Quezada SA, Wade TK, Barth RJ Jr, Noelle RJ, Wade WF (2003). Distinctive maturation of *in vitro* versus *in vivo* anti-CD40 mAb-matured dendritic cells in mice. *J Immunother* 26 (1): 72-84.

Barth RJ, Gibson G, Carney P, Mott L, Becher R, Poplack S. (2005) Detection of breast cancer by screening mammography allows patients to be treated with less toxic therapy, *Am J Roentgenology*, 184: 324-9.

Pipas, JM, Barth RJ, Zaki B, Tsapakos M, Bettmann M, Cates J, Suriawinata A, Ripple G, Sutton J, Gordon S, McDonnell C, Perez R, Redfield N, Meyer L, Marshal J, Cole B, Colacchio T. (2005). Docetaxel/gemcitabine followed by Gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma, *Ann Surg Onc.* 12: 995-1004.

Greer S, Pipas J, Sutton J, Zaki B, Tsapakos M, Colacchio T, Gibson J, Wiener, D, Ripple, G, Barth RJ. Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma. *J Am Coll Surg* 2008, 206: 451-457.

Gorechlad J, McCabe E, Higgins J, Likosky D, Lewis P, Rosenkranz K, Barth RJ. Screening for Recurrences in Patients Treated with Breast Conserving Surgery: Is there a Role for MRI? *Ann Surg Onc* 2008: 15: 1703-9.

### **Recently Completed Research Support**

5 R29CA76612-05 Barth (PI)

07/01/98 – 06/30/04

NIH

Mechanisms underlying CD40L's role in tumor immunity

The goal of this project is to explore the cellular mechanisms by which CD40 activation leads to anti-tumor immunity in murine models.

P20 RR16437 Barth (PI of Project 5), William Green, PhD overall PI

10/01/01 – 12/31/04

NIH

A trial of a CD40 activated dendritic cell vaccine in patients with resected colorectal cancer

The purpose of this study is to evaluate the immunologic effectiveness of a CD40L activated, intranodally injected DC vaccine in patients as part of a clinical trial, and evaluate new vaccines in mouse models.

### **C. Current Research Support**

2 PO1 CA080139-06A1 (Paulsen, Keith, PI)  
NIH.

Period: 4/06-4/11  
Co-investigator 5% effort

Alternative Breast Cancer Imaging Modalities

The goal of this project is to validate the use of new imaging methods for palpable breast masses.

2 P30 CA023108-27 (Israel, Mark A., P.I.)

Period: 12/1/2003-11/30/2008 10% effort

NIH

\$1,828,696 Total Award

Norris Cotton Cancer Center Support Grant

(\$16,676 salary support only)

The major goal of this project is to provide funding for the Norris Cotton Cancer Center. The Cancer Center is a multidisciplinary focus for cancer-related research, education, and patient care. This supports my efforts as co-PI of the Immunology and Cancer Immunotherapy Research Program.